

Ming Chen

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4057021/publications.pdf](https://exaly.com/author-pdf/4057021/publications.pdf)

Version: 2024-02-01

33
papers

2,308
citations

328504

20
h-index

465588

28
g-index

35
all docs

35
docs citations

35
times ranked

5410
citing authors

#	ARTICLE	IF	CITATIONS
1	Heat shock factor 1 directly regulates transsulfuration pathway to promote prostate cancer proliferation and survival. <i>Communications Biology</i> , 2024, 7, .	4.5	2
2	Tracking down metabolic vulnerabilities in <i>CDK12</i> mutant prostate cancer. <i>Clinical and Translational Discovery</i> , 2024, 4, .	0.6	0
3	Nuclear PTEN Regulates Thymidylate Biosynthesis in Human Prostate Cancer Cell Lines. <i>Metabolites</i> , 2023, 13, 939.	3.0	0
4	Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis. <i>Nature Communications</i> , 2019, 10, 3716.	13.0	21
5	The expanded role of fatty acid metabolism in cancer: new aspects and targets. <i>Precision Clinical Medicine</i> , 2019, 2, 183-191.	3.3	131
6	Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling. <i>Cell Communication and Signaling</i> , 2019, 17, 120.	6.7	52
7	Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. <i>Science</i> , 2019, 364, .	19.8	211
8	Vulnerabilities in <i>mIDH2</i> AML confer sensitivity to APL-like targeted combination therapy. <i>Cell Research</i> , 2019, 29, 446-459.	12.1	34
9	SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. <i>Developmental Cell</i> , 2019, 48, 329-344.e5.	7.0	56
10	Deregulated <i>PP1δ</i> phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. <i>Nature Communications</i> , 2018, 9, 159.	13.0	40
11	An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. <i>Nature Genetics</i> , 2018, 50, 206-218.	20.2	240
12	Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. <i>Nature Medicine</i> , 2018, 24, 165-175.	29.9	148
13	Molecular Genetics of APL. , 2018, , 41-53.		1
14	Preclinical and Coclinical Studies in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030544.	6.3	3
15	Loss of <i>LDAH</i> associated with prostate cancer and hearing loss. <i>Human Molecular Genetics</i> , 2018, 27, 4194-4203.	3.0	14
16	The functions and regulation of the PTEN tumour suppressor: new modes and prospects. <i>Nature Reviews Molecular Cell Biology</i> , 2018, 19, 547-562.	36.9	609
17	Compound haploinsufficiency of <i>Dok2</i> and <i>Dusp4</i> promotes lung tumorigenesis. <i>Journal of Clinical Investigation</i> , 2018, 129, 215-222.	6.6	18
18	The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. <i>Cancer Discovery</i> , 2017, 7, 424-441.	14.1	63

#	ARTICLE	IF	CITATIONS
19	Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling. American Journal of Pathology, 2016, 186, 3131-3145.	4.1	31
20	Endosome and INPP4B. Oncotarget, 2016, 7, 5-6.	1.9	18
21	<i>In Vivo</i> Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. Cancer Discovery, 2015, 5, 740-751.	14.1	89
22	Suppression of <i>CHK1</i> by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discovery, 2015, 5, 550-563.	14.1	25
23	Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Research, 2015, 75, 4384-4397.	0.9	76
24	Vulnerabilities of <i>PTEN</i> - <i>TP53</i> -Deficient Prostate Cancers to Compound PARP-PI3K Inhibition. Cancer Discovery, 2014, 4, 896-904.	14.1	88
25	Loss of epithelial oestrogen receptor β inhibits oestrogen-stimulated prostate proliferation and squamous metaplasia via <i>in vivo</i> tissue selective knockout models. Journal of Pathology, 2012, 226, 17-27.	4.4	32
26	Reduced prostate branching morphogenesis in stromal fibroblast, but not in epithelial, estrogen receptor β knockout mice. Asian Journal of Andrology, 2012, 14, 546-555.	1.8	14
27	Defects of Prostate Development and Reproductive System in the Estrogen Receptor- β Null Male Mice. Endocrinology, 2009, 150, 251-259.	2.8	67
28	CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells. Carcinogenesis, 2009, 30, 841-850.	2.8	56
29	Generation and characterization of a complete null estrogen receptor β mouse using Cre/LoxP technology. Molecular and Cellular Biochemistry, 2009, 321, 145-153.	3.1	46
30	ERAP75 functions as a coactivator to enhance estrogen receptor β transactivation in prostate stromal cells. Prostate, 2008, 68, 1273-1282.	2.3	15
31	ROLES OF VITAMIN E IN PROSTATE AND PROSTATE CANCER. , 2005, , 263-276.		1
32	FUNCTIONS OF ESTROGEN RECEPTOR IN PROSTATE AND PROSTATE CANCER. , 2005, , 293-313.		0
33	Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochemical and Biophysical Research Communications, 2003, 300, 357-363.	2.2	107